Skip to main content
SCYNEXIS INC logo

SCYNEXIS INC — Investor Relations & Filings

Ticker · SCYX ISIN · US8112922005 LEI · 529900XBHFGMNTU70154 US Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2015-03-18 Investor Presentation
Country US United States of America
Listing US SCYX

About SCYNEXIS INC

https://www.scynexis.com/

SCYNEXIS, Inc. is a biotechnology company focused on the discovery and development of novel anti-infectives to overcome difficult-to-treat and drug-resistant fungal infections. The company is pioneering a new class of broad-spectrum antifungal agents called 'fungerps,' which are triterpenoid-based compounds. These agents are being developed in both oral and intravenous formulations to treat a range of serious, invasive, and life-threatening fungal diseases, particularly those encountered in hospital environments. SCYNEXIS aims to address the significant global health threat of antifungal resistance by providing innovative therapeutic options where existing treatments are limited or ineffective. The company's development pipeline includes second-generation fungerp candidates.

Recent filings

Filing Released Lang Actions
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed by SCYNEXIS, Inc. It specifically mentions Item 7.01 Regulation FD Disclosures and includes a Corporate Presentation as Exhibit 99.1. The text states that the presentation will be made at the Jefferies 2015 Antibiotic Summit and that the presentation is attached. The document is 3343 characters long, which is relatively short and primarily serves to announce and attach a presentation rather than provide a full detailed report. The content is consistent with an Investor Presentation (IP) rather than a full Annual Report, Earnings Release, or other financial report. The document is not a report publication announcement since it includes the presentation itself as an exhibit. Therefore, the best classification is Investor Presentation (IP).
2015-03-18 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC. It registers additional shares of common stock under the company's equity incentive and employee stock purchase plans. The document includes details about the number of shares, plans, and legal exhibits, but it is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2015-03-17 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated February 25, 2015. It specifically reports the appointment of a new board member, Steven C. Gilman, Ph.D., to the company's Board of Directors and committees, along with details about his compensation arrangement. The key section is Item 5.02, which relates to the departure or election of directors or officers. There are no financial statements or earnings data, nor is this a full annual or quarterly report. The content clearly fits the category of announcements about changes in the company's board or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 3007 characters, which is consistent with a typical 8-K filing for management changes, not a full report or announcement of a report publication.
2015-03-03 English
FORM 4
Director's Dealing
2015-02-27 English
FORM 3
Director's Dealing
2015-02-27 English
SC 13G/A
Major Shareholding Notification
2015-02-17 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.